Table 1.
Patient demographics, clinical characteristics, and ECT treatment information.
| Demographics | CLINICAL INFORMATION | ECT INFORMATION | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Sex (M/F) | Age | Dx | QIDS | Antidepressant | Mood stabilizer | BZD | Antipsychotic | Stimulant | Tx # | Total Tx | Laterality | Pulse width (msec) | Stimulus (%) | Seizure (sec) | Anesthesia |
| 1 | FTM | 30 s | MDD, PTSD, Unspecified anxiety |
21 9 |
DUL DUL |
1 8 |
10 10 |
BL RUL |
0.3 0.5 |
10 50 |
300 117 |
MTX, SUX MTX, SUX, Alfent, CAFF |
||||
| 2 | M | 50 s |
MDD, PTSD, Alcohol use d/o |
20 17 |
VEN VEN |
Lithium Lithium |
1 3 |
3 3 |
BL BL |
0.5 0.5 |
30 30 |
69 76 |
MTX, SUX MTX, SUX |
|||
| 3 | F | 40 s | MDD, PTSD, Eating d/o |
20 18 |
FLU, BUP NTP |
1 7 |
9 9 |
BL BL |
0.5 0.5 |
10 40 |
163 50 |
MTX, SUX MTX, SUX, CAFF |
||||
| 4 | M | 60 s |
MDD, Alcohol use d/o |
14 10 |
MIR MIR |
Quetiapine Quetiapine |
8 12 |
12 12 |
BL BL |
0.5 0.5 |
75 100 |
38 36 |
MTX, SUX, CAFF MTX, SUX, CAFF |
|||
| 5 | M | 40 s |
Bipolar II d/o, Polysubstance abusea |
11 9 |
BUP, DUL BUP, DUL |
Lurasidone Lurasidone |
4 12 |
12 12 |
BL BL |
0.5 0.5 |
60 100 |
36 59 |
MTX, SUX MTX, SUX, Alfent, CAFF, Glycopyr |
|||
| 6 | M | 60 s |
Bipolar II d/o, PTSD, Social anxiety |
18 8 |
DUL DUL |
Lorazepam Lorazepam |
Ritalin Ritalin |
2 12 |
12 12 |
RUL RUL |
0.5 0.5 |
60 90 |
35 21 |
MTX, SUX, Alfent MTX, SUX, Alfent |
||
| 7 | M | 50 s |
MDD, PTSD Alcohol use d/o |
22 20 15 |
VEN VEN VEN |
Quetiapine Quetiapine Quetiapine |
1 4 7 |
7 7 7 |
BL BL BL |
0.5 0.5 0.3 |
30 50 100 |
25 134 18 |
MTX, SUX MTX, SUX, Alfent MTX, SUX, Alfent, CAFF, KET |
|||
| 8 | M | 30 s | MDD, PTSD, |
18 14 |
FLU, MIR FLU, MIR |
1 4 |
10 10 |
BL BL |
0.3 0.3 |
10 20 |
66 71 |
MTX, SUX MTX, SUX |
||||
| 9 | M | 40 s |
MDD, PTSD, Alcohol use d/o |
23 19 - 15 |
DUL DUL DUL |
Risperidone |
1 5 9 12 |
12 12 12 12 |
BL BL BL BL |
0.3 0.3 0.5 0.5 |
5 10 80 100 |
130 40 64 43 |
MTX, SUX MTX, SUX, Glycopyr MTX, SUX, Glycopyr MTX, SUX, Glycopyr |
|||
BUP bupropion, ESC escitalopram, DUL duloxetine, FLU fluoxetine, MIR mirtazapine, NTP nortriptyline, VEN venlafaxine, MTX methotrexate, SUX succinylcholine, Alfent alfentanil, CAFF caffeine, Glycopyr glycopyrrolate, KET ketamine.
aPolysubstance abuse is no longer a DSM-V diagnosis. The patient for which that is listed was using Alcohol, Cannabis, Cocaine, Amphetamine and Opioid Dependence. All, apparently, in remission (not used for at least 1 year).